Here's some of what is coming soon to NeurologyLive® this week.
|Slideshows|May 10, 2016
Interesting Neuro: Alzheimer & Parkinson insights
Author(s)Samantha J. Peterson
Our May news includes memory replay disruption in Alzheimer disease, impulse control disorder in Parkinson disease, and return to play in TBI.
Advertisement
We present a selection of interesting neurology articles for the month of May in the following slides. See the slide legends for links to the article summaries.
Advertisement
Related to this article
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 18, 2026.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 25, 2026.
FDA approves once-daily oral tavapadon for Parkinson disease, a first-in-class D1/D5 partial agonist that improves motor function and ON time, with key safety warnings.
The FDA lifted a clinical hold on simufilam, clearing Filana Therapeutics, formerly Cassava Sciences, to begin a phase 2a study in TSC-related epilepsy.
PridCor Therapeutics is moving its phase 2 SHIELD trial of a combination antiviral regimen toward enrollment, building on case series data showing durable symptom improvement in long COVID.
In a discrete choice experiment, somnolence risk and short-term efficacy were the top factors driving vesicular monoamine transporter 2 inhibitor selection for tardive dyskinesia in patients aged 55 years and older.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Tavapadon for the Treatment of Parkinson Disease
2
FDA Extends Relutrigine Review, Delays PDUFA to December
3
Gefurulimab Cuts Hospitalizations, Sustains Response in Phase 3 PREVAIL Trial of Myasthenia Gravis
4
This Week on NeurologyLive® — September 28, 2026
5